Utility of 18F-Florzolotau PET as a prognostic and monitoring biomarker in a memory clinic cohort

Tau PET is increasingly recognized for its prognostic and disease-monitoring value in Alzheimer’s disease (AD); however, real-world evidence in heterogeneous memory clinic populations remains limited, especially for novel tau positron emission tomography (PET) with 18F-Florzolotau. We prospectively enrolled 340 individuals (patients with cognitive complaints and community volunteers) undergoing baseline amyloid PET and tau PET with 18F-Florzolotau, with subsets for clinical follow-up (n = 260; median interval 1.45 [0.96–2.56] years) and repeat tau PET (n = 64; median interval 2.27 [1.47–2.88] years). The incremental prognostic role of tau PET beyond demographic and clinical characteristics was assessed using binary clinical outcomes and continuous cognitive declines. The monitoring utility of tau PET was evaluated through tau accumulation rates versus clinical outcomes, and cognition-tau correlations. Cross-sectionally, tau standardized uptake value ratios (SUVRs) increased with cognitive impairment severity and correlated with domain-specific deficits. Longitudinally, baseline tau SUVRs provided incremental prognostic value, with higher neocortical SUVR as the sole independent predictor beyond demographic and clinical characteristics, particularly in AD spectrum (HR = 1.62, p = 0.018). Accelerated tau deposition was observed in motor regions including the precentral gyrus (β = 0.07 SUVR/year, p = 0.007) and supplementary motor area (β = 0.08 SUVR/year, p = 0.017) in those clinically progressive individuals than stable counterparts. Critically, these motor regions showed stronger cognition-tau correlations than canonical tau-vulnerable regions (medial temporal lobe and neocortex), establishing them as superior monitoring biomarkers. 18F-Florzolotau PET provides significant prognostic value and enables AD progression tracking. Motor cortices offered enhanced sensitivity for monitoring clinical deterioration in symptomatic stages, supporting their integration into stage-specific frameworks.

Authors

Institutions

Publication Details

Journal
Alzheimer s Research & Therapy
Published
2025-12-18
DOI
https://doi.org/10.1186/s13195-025-01938-w
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Utility of 18F-Florzolotau PET as a prognostic and monitoring biomarker in a memory clinic cohort

Zizhao Ju, Huiwei Zhang, Senxiang Yan, Jiaying Lu et al.
Alzheimer s Research & Therapy
Dementia and Cognitive Impairment Research
article

Utility of 18F-Florzolotau PET as a prognostic and monitoring biomarker in a memory clinic cohort

Zizhao Ju, Huiwei Zhang, Senxiang Yan, Jiaying Lu, Chuantao Zuo, Qianhua Zhao, Huamei Lin, Tzu‐Chen Yen, Yihui Guan, Zhenxu Xiao, Xiaoxi Ma, Fangyang Jiao, Jingjie Ge, Ming Li, Min Wang, Ding Ding, Yang Liu, Jie Wu, Jie Wang, Weiqi Bao, Li Zheng, Yunhao Yang, Xiaoniu Liang, Xiaowen Zhou
article en

Abstract

Tau PET is increasingly recognized for its prognostic and disease-monitoring value in Alzheimer’s disease (AD); however, real-world evidence in heterogeneous memory clinic populations remains limited, especially for novel tau positron emission tomography (PET) with 18F-Florzolotau. We prospectively enrolled 340 individuals (patients with cognitive complaints and community volunteers) undergoing baseline amyloid PET and tau PET with 18F-Florzolotau, with subsets for clinical follow-up (n = 260; median interval 1.45 [0.96–2.56] years) and repeat tau PET (n = 64; median interval 2.27 [1.47–2.88] years). The incremental prognostic role of tau PET beyond demographic and clinical characteristics was assessed using binary clinical outcomes and continuous cognitive declines. The monitoring utility of tau PET was evaluated through tau accumulation rates versus clinical outcomes, and cognition-tau correlations. Cross-sectionally, tau standardized uptake value ratios (SUVRs) increased with cognitive impairment severity and correlated with domain-specific deficits. Longitudinally, baseline tau SUVRs provided incremental prognostic value, with higher neocortical SUVR as the sole independent predictor beyond demographic and clinical characteristics, particularly in AD spectrum (HR = 1.62, p = 0.018). Accelerated tau deposition was observed in motor regions including the precentral gyrus (β = 0.07 SUVR/year, p = 0.007) and supplementary motor area (β = 0.08 SUVR/year, p = 0.017) in those clinically progressive individuals than stable counterparts. Critically, these motor regions showed stronger cognition-tau correlations than canonical tau-vulnerable regions (medial temporal lobe and neocortex), establishing them as superior monitoring biomarkers. 18F-Florzolotau PET provides significant prognostic value and enables AD progression tracking. Motor cortices offered enhanced sensitivity for monitoring clinical deterioration in symptomatic stages, supporting their integration into stage-specific frameworks.

Alzheimer s Research & TherapyVol. 18(1)
Shanghai University (CN), Chang Gung University (TW), Fudan University (CN), Chang Gung Memorial Hospital (TW), Huashan Hospital (CN)
Openalex Percentile: Top 52%
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.